Inside STAT: How patients in Alzheimer’s trials are coping with the treatment’s failure

JEFF BORGHOFF, ONE OF THE ADUCANUMAB TRIAL PARTICIPANTS (COURTESY OF JEFF BORGHOFF)

When Biogen and Eisai announced last month they were stopping two Phase 3 trials of the Alzheimer’s treatment aducanumab because the drug wasn’t likely to prove effective, it shattered the faith that a therapy against the neurodegenerative disease was finally in reach. But to the roughly 3,200 people in the trials and their families, the disappointment was particularly acute. These people must now reconcile with the fact that aducanumab hadn’t been staving off their disease, and that there isn’t another option available to them. STAT’s Andrew Joseph has the story here.